Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE Study for HER2-positive Early Breast Cancer (eBC)
Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESCO 2018
Shots:
- The P-III KATHERINE study assessed Kadcyla vs Herceptin (trastuzumab) as an adjuvant therapy for patients with HER2-positive eBC for three years
- P-III KATHERINE study results: risk of disease recurrence or death 50%; didn’t have breast cancer return (88.3% vs 77.0%); with no new safety issues
- Kadcyla is an antibody-drug conjugate (ADC) developed for delivering CT directly to HER2-positive cancer cells and is approved in 104 countries including the US and EU for HER2-positive metastatic breast cancer
Click here to read full press release/ article | Ref: Roche | Image: Roche